Avricore Health Inc. (AVCRF)
| Previous close | 0.0690 |
| Open | 0.0690 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0690 - 0.0690 |
| 52-week range | 0.0210 - 0.2044 |
| Volume | |
| Avg. volume | 2,153 |
| Market cap | 11.3M |
| Beta (5Y monthly) | -2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAvricore Health Corporate Update and Audited Results for 2023
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce its audited results for 2023. The Company nearly doubled its previous record revenues to $3,485,147 while gross profit increased by 163% to $1,203,396. The Company is currently in an early scale-up and growth period, and therefore has made substantial capital investments with on-hand cash during this period, and yet strong gross margins have allowed t
- GlobeNewswire
HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce further expansion of HealthTab™ with Rexall Pharmacy Group ULC (“Rexall”). The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform. “To successfully screen and manage chronic and infectious disea
- GlobeNewswire
Avricore Health Corporate Update – Company Demonstrates Strong Growth
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of t
